Overview

A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)

Status:
Active, not recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label, non-randomized, study of pembrolizumab (PBZ) in combination with cisplatin (CIS) and pemetrexed (PMX) in treatment of naïve participants with a histologically confirmed diagnosis of advanced/unresectable malignant pleural mesothelioma (MPM) in Japanese participants. This study will evaluate the safety, tolerability, and preliminary efficacy of PBZ in combination with CIS and PMX. The primary objective is to evaluate the safety and tolerability of treatment with PBZ in combination with CIS and PMX.

Phase:

Phase 1

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Cisplatin
Pembrolizumab
Pemetrexed